Health claims science hits the economic bottom line

By Stephen Daniells

- Last updated on GMT

Related tags: Economics, Nutrition, Health

Producing randomized clinical trials is never an inexpensive endeavour, but increasingly stringent criteria mean companies are facing tough choices on whether to pursuer innovation, says DSM Nutritional Products.

In this round-table discussion, DSM Nutritional Products’ Bas van Buijtenen, VP human nutrition and health, and Dr Volker Schehlmann, program director, tell Stephen Daniells how EFSA’s approach to science may impede innovation in the EU.

“The investment that is required to fully substantiate a claim according to the criteria that are being defined is larger than it was before,” ​said van Buijtenen. “The path to market is becoming very long,”​ he added.

“At which point in time do you allow entry to market, do you allow the claim to be made?​” asked van Buijtenen. “If you push that further and further back in time it will absolutely affect the economics of any decision you make at the early stages of such a process, and am I going to pursue this investment in innovation.”

Related topics: Research, Suppliers, Health claims

Related news

Show more

Follow us


View more